SCHEMBL3987074

SCHEMBL3987074

NC(CCC(=O)O)c1cc(F)c(F)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.39
GABRD O14764 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRB1 P18505 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
GABRA2 P47869 2/20 0.39
GABRB2 P47870 2/20 0.39
GABRA4 P48169 2/20 0.39
GABRE P78334 2/20 0.39
GABRA6 Q16445 2/20 0.39
GABRG1 Q8N1C3 2/20 0.39
GABRG3 Q99928 2/20 0.39
GABRQ Q9UN88 2/20 0.39
SLC1A3 P43003 2/20 0.39
SLC1A2 P43004 2/20 0.39
SLC1A1 P43005 2/20 0.39
GRM8 O00222 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28033030 0.80 ADRA2A (0.39) CYP2D6NFKB1BLMMAPTTET2
SCHEMBL28048592 0.79 GABRP (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15155706 0.79 GABRP (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL23217529 0.77 GAA (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL28228203 0.76 GABRP (0.33) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL28246724 0.73 DPP4 (0.37) DPP4
SCHEMBL2318494 0.73 DPP4 (0.31) DPP4
SCHEMBL8515283 0.72 ADRB2 (0.36) BLMMAPTDPP4KDM4C
SCHEMBL28021058 0.72 ADRB2 (0.36) BLMMAPTDPP4KDM4C
SCHEMBL7453656 0.69 FOLH1 (0.45) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203550-A1 USE OF STEREOSELECTIVE TRANSAMINASE IN ASYMMETRIC SYNTHESIS OF CHIRAL AMINE ABIOCHEM BIOTECHNOLOGY CO., LTD (CN) 2023-06-29 US claimed
CN-104130149-B A kind of recoverying and utilizing method of 3-(S)-amino butyric acid derivative ZHEJIANG CHANGMING PHARMACEUTICAL CO., LTD. (CN) 2016-01-27 CN claimed
CN-104130149-A Recycling method of 3-(S)-aminobutyric acid derivative ZHEJIANG CHANGMING PHARMACEUTICAL CO LTD 2014-11-05 CN claimed
CN-109896980-A A kind of biological synthesis method of sitagliptin intermediate 浙江九洲药业股份有限公司 2019-06-18 CN disclosed
CN-109824546-A BOC- (R) -3- amino -4- (2,4,5- trifluorophenyl) butyric acid is condensed impurity and preparation method thereof 浙江永太科技股份有限公司 2019-05-31 CN disclosed
CN-109608348-A A kind of synthetic method of (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl) butyric acid 凯瑞斯德生化(苏州)有限公司 2019-04-12 CN disclosed
CN-105294479-B A kind of 3R amino replaces the preparation method of butanamide derivatives 新发药业有限公司 2017-09-22 CN disclosed
CN-106966940-A A kind of preparation method of Sitagliptin phosphate intermediate N arylmethyls 2S cyano methyl acridines 新发药业有限公司 2017-07-21 CN disclosed
CN-105061434-B Preparation method of sitagliptin phosphate 新发药业有限公司 2017-07-21 CN disclosed
CN-106801043-A One kind restructuring transaminase and its preparation method and application 江苏阿尔法药业有限公司 2017-06-06 CN disclosed
CN-103483340-B A kind of synthetic method of sitagliptin 无锡佰翱得生物科学有限公司 2016-09-07 CN disclosed
CN-104130149-B A kind of recoverying and utilizing method of 3-(S)-amino butyric acid derivative ZHEJIANG CHANGMING PHARMACEUTICAL CO., LTD. (CN) 2016-01-27 CN disclosed
CN-104130149-A Recycling method of 3-(S)-aminobutyric acid derivative ZHEJIANG CHANGMING PHARMACEUTICAL CO LTD 2014-11-05 CN disclosed
WO-2013114173-A1 A NOVEL PROCESS FOR THE PREPARATION OF SITAGLIPTIN SMILAX LABORATORIES LIMITED (IN) 2013-08-08 WO disclosed
CN-102159578-A Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO 2011-08-17 CN disclosed
US-20090192326-A1 Preparation of sitagliptin intermediate TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-07-30 US disclosed
WO-2009064476-A1 PREPARATION OF SITAGLIPTIN INTERMEDIATE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192326-A1 Preparation of sitagliptin intermediate DPP4, DPP7, DPP3 GABRP 1223/4885GABRD 1396/4885GABRA1 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.